First Financial Bankshares Inc Purchases 7,509 Shares of Merck & Co., Inc. $MRK

First Financial Bankshares Inc boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 728,519 shares of the company’s stock after acquiring an additional 7,509 shares during the period. Merck & Co., Inc. makes up approximately 1.5% of First Financial Bankshares Inc’s holdings, making the stock its 24th largest holding. First Financial Bankshares Inc’s holdings in Merck & Co., Inc. were worth $76,684,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. Brighton Jones LLC increased its stake in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares during the period. Sivia Capital Partners LLC increased its stake in Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the period. Diversify Advisory Services LLC increased its stake in Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares during the period. Diversify Wealth Management LLC increased its stake in Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after acquiring an additional 359,356 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRK. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research note on Friday, February 13th. Wells Fargo & Company lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Barclays began coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Finally, Citigroup initiated coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Up 1.4%

MRK stock opened at $120.81 on Friday. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $125.14. The firm has a market cap of $298.37 billion, a P/E ratio of 34.03, a P/E/G ratio of 2.68 and a beta of 0.21. The business’s 50 day moving average is $116.59 and its 200-day moving average is $113.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the company posted $2.22 EPS. The company’s revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, adding a biodevice company focused on poultry performance and strengthening Merck’s animal health growth platform. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: MRK regained its 50-day moving average and remains above its 200-day trendline, with articles pointing to Keytruda growth, pipeline advances, and recent deals as supporting factors. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Positive Sentiment: Wells Fargo reiterated its Buy rating on Merck, reinforcing a constructive analyst view on the stock. Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
• Neutral Sentiment: Recent “most searched stocks” and market commentary indicate rising investor attention, but do not point to a specific new fundamental development for MRK. Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
• Neutral Sentiment: Broader healthcare-dealmaking momentum may be supportive for sector sentiment, but it is an indirect driver for Merck rather than a company-specific catalyst. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
• Neutral Sentiment: Articles highlighting Merck’s recent outperformance versus its moving averages and strong Keytruda franchise are supportive, but largely reflect ongoing investor optimism rather than a new surprise. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Negative Sentiment: One market note said Merck rose but still lagged the broader market, implying investors may be favoring faster-moving names elsewhere despite MRK’s gains. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.